Skip to main
TARA
TARA logo

TARA Stock Forecast & Price Target

TARA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protara Therapeutics is positioned favorably in the oncology and rare disease markets through its lead program, TARA-002, which is demonstrating promising interim efficacy and durability data, supporting its potential as a first-mover in the BCG-naïve setting. The company’s strategy includes robust engagement with the FDA, outlining a clear registrational pathway for TARA-002, which enhances its prospects for capturing substantial market share in both the BCG-naïve and BCG-unresponsive patient populations. Additionally, the positive interim results from trials in lymphatic malformations reinforce Protara's potential for sustainable and low-risk value creation, augmenting its overall investment appeal.

Bears say

Protara Therapeutics Inc faces significant financial risks primarily due to its reliance on the successful development and commercialization of its limited portfolio, particularly TARA-002 and IV choline chloride. The company's valuation may be adversely impacted by potential regulatory hurdles, extended timelines for clinical trials, and the uncertainty of achieving commercial viability for its therapies in a competitive market. Additionally, ongoing funding requirements and potential cash flow issues could further strain the company’s financial position, raising concerns among investors regarding its long-term sustainability.

TARA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protara Therapeutics Inc (TARA) Forecast

Analysts have given TARA a Buy based on their latest research and market trends.

According to 4 analysts, TARA has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protara Therapeutics Inc (TARA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.